Tumors

San Francisco, CA

201 Tumors Trials near San Francisco, CA

Power is an online platform that helps thousands of Tumors patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Chemotherapy + Radiation for Soft Tissue Sarcoma

San Francisco, California
This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:2+

140 Participants Needed

Chemotherapy + Radiation for Kidney Cancer (Wilms' Tumor)

San Francisco, California
This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more tumor cells.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:< 29

395 Participants Needed

Chemotherapy +/− Radiation for Kidney Cancer

San Francisco, California
This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors.Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:< 29

808 Participants Needed

Chemotherapy for Wilms Tumor

San Francisco, California
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:< 30

256 Participants Needed

Hyperpolarized 13C Pyruvate MRI for Kidney Cancer

San Francisco, California
This feasibility study will evaluate how well hyperpolarized 13C pyruvate magnetic resonance imaging (MRI) scan works in predicting tumor aggressiveness in participants with renal tumors. Hyperpolarized 13C pyruvate is a non-radioactive substance with potential usage in the diagnostic imaging of tumors. Hyperpolarized 13C pyruvate MRI may help doctors determine non-invasively whether a kidney tumor is a benign tumor or cancer, and if cancer, how aggressive it is. This may help doctors and participants with renal tumors in the future to make better treatment decisions.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

100 Participants Needed

NK Cell Therapy for Pediatric Brain Cancer

San Francisco, California
This trial uses enhanced immune cells called natural killer cells to treat children and young adults with recurring or worsening brain tumors. The treatment involves injecting these cells directly into the tumor to help destroy cancer cells. Natural killer (NK) cells are a promising option in cancer immunotherapy, showing potential in treating various solid tumors, including brain tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:1 - 38

24 Participants Needed

GM T Cell Therapy Long-Term Follow-Up for Cancer

San Francisco, California
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

1541 Participants Needed

GSK4524101 + Niraparib for Cancer

San Francisco, California
This trial is testing a new drug called GSK4524101 alone and with another drug called niraparib. It aims to find the highest safe dose and understand its effects, likely targeting cancer patients who need new treatment options. Niraparib is a drug taken by mouth that is used to maintain treatment in ovarian cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

135 Participants Needed

Dostarlimab for Advanced Cancer

San Francisco, California
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

738 Participants Needed

GSK4381562 for Cancer

San Francisco, California
This trial tests a new drug called GSK4381562 in patients with recurring or spreading tumors who have no other treatment options. It will see how the drug is processed by the body, its safety, and any immune responses it might cause.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

158 Participants Needed

MK-4830 + Pembrolizumab for Cancer

San Francisco, California
This trial is testing a new drug called MK-4830 alone and with other cancer treatments to see if it is safe and effective. It focuses on cancer patients, including those in China. The treatments work by helping the immune system fight cancer and killing cancer cells.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

442 Participants Needed

RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant for Breast Cancer

San Francisco, California
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

540 Participants Needed

Iobenguane (131-I) + Vorinostat for Neuroblastoma

San Francisco, California
This trial tests a combination of a radioactive drug and a cancer-fighting pill in patients with a specific type of neuroblastoma that hasn't responded well to other treatments. The radioactive drug kills cancer cells, and the pill makes them more vulnerable to the drug.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:1+

60 Participants Needed

Nivolumab + DAY101 for Craniopharyngioma

San Francisco, California
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:1 - 39

57 Participants Needed

GIM-531 for Solid Tumors

San Francisco, California
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

117 Participants Needed

Lenvatinib + Pembrolizumab for Neuroendocrine Cancer

San Francisco, California
This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). First described in the pancreas in 2017, the classification was broadened to include gastrointestinal tract tumors in 2019. Recent data suggest an equivalent subtype exists in the lungs (NEC with carcinoid morphology). WD G3 NETs can occur de novo as well as the result of grade progression over time. This is a single arm, multi-site, Phase II study in biomarker "unselected" participants. This study will also incorporate serial blood samples, tumor biopsies, and special imaging to better understand the impact of therapy on the tumor and microenvironment. Hyperpolarized (HP) 13C-pyruvate magnetic resonance imaging (MRI) - a novel non-radioactive imaging modality able to provide in vivo measurements of the pyruvate-to-lactate conversion rate (kpl).
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

29 Participants Needed

Tocilizumab + Atezolizumab + Radiation Therapy for Glioblastoma

San Francisco, California
This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

59 Participants Needed

VT3989 for Mesothelioma

San Francisco, California
This trial tests a new drug, VT3989, for safety and effectiveness in patients with certain types of cancer that don't respond to other treatments. Researchers aim to find the best dose and see if the drug can help control the cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

336 Participants Needed

Multiple Targeted Therapies for Meningioma

San Francisco, California
This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

124 Participants Needed

NST-628 for Cancer

San Francisco, California
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

230 Participants Needed

Why Other Patients Applied

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

DSP-0390 for Brain Tumor

San Francisco, California
This trial is testing a new drug called DSP-0390 in patients with a type of brain cancer that has returned after treatment. The goal is to see if this drug can help stop or slow down the cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1

39 Participants Needed

FAP-2286 Imaging for Cancer

San Francisco, California
This trial tests a new imaging dye that helps doctors see cancer spread in patients with various solid tumors. The dye sticks to a specific protein in cancer cells and lights up on scans.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

131 Participants Needed

Immunotherapy Before and After Surgery for Brain Tumor

San Francisco, California
This trial studies the effects of nivolumab, an immunotherapy drug, in children and young adults with severe brain cancer that has returned or worsened. The drug helps the immune system fight the cancer and may prevent it from growing.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:6 - 25

20 Participants Needed

PF-07799544 for Cancer

San Francisco, California
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:16+

124 Participants Needed

Stereotactic Radiosurgery for Meningioma

San Francisco, California
This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Hypofractionated stereotactic radiosurgery may be safe, tolerable, and effective in treating patients with grade II or recurrent grade I meningiomas after surgical resection.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

23 Participants Needed

BMX-001 + Chemoradiation for Brain Cancer

San Francisco, California
This trial tests BMX-001, an injectable drug, added to standard radiation and chemotherapy for newly diagnosed aggressive brain cancer patients. The goal is to see if BMX-001 can improve survival and protect brain function.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

160 Participants Needed

Focused Ultrasound BBBD for Glioblastoma

San Francisco, California
This trial aims to test the safety and effectiveness of using the Exablate device to temporarily open the blood-brain barrier in patients with suspected Glioblastoma. By doing this, doctors can collect fluid from the brain to check for cancer cells. The study will take place at up to 25 centers in the US.
No Placebo Group

Trial Details

Trial Status:Recruiting

57 Participants Needed

CGT9486 + Sunitinib for GIST

San Francisco, California
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner. Additionally, a drug-drug interactions substudy will investigate the potential for CGT9486 to be a CYP3A4 inducer in approximately 16 patients who have received at least one prior line of therapy for GIST.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

442 Participants Needed

Pembrolizumab for Advanced Cancers

San Francisco, California
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

3500 Participants Needed

Niraparib Maintenance Treatment for Ovarian Cancer

San Francisco, California
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Female

733 Participants Needed

1...345...7

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Tumors clinical trials in San Francisco, CA pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Tumors clinical trials in San Francisco, CA work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Tumors trials in San Francisco, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in San Francisco, CA for Tumors is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in San Francisco, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Tumors medical study in San Francisco, CA?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Tumors clinical trials in San Francisco, CA?

Most recently, we added Metformin for Brain Tumor, Counseling for Brain Cancer and Imaging Agent 111In-ABD147 for Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in California

Anxiety Clinical Trials in California

Schizophrenia Clinical Trials in California

ADHD Clinical Trials in California

Bipolar Disorder Clinical Trials in California

Multiple Sclerosis Clinical Trials in California

Autism Clinical Trials in California

Treatment Resistant Depression Clinical Trials in California

Borderline Personality Disorder Clinical Trials in California

Social Anxiety Disorder Clinical Trials in California

Parkinson's Disease Clinical Trials in California

Alzheimer's Disease Clinical Trials in California

By Location

Clinical Trials near Los Angeles, CA

Clinical Trials near San Francisco, CA

Clinical Trials near San Diego, CA

Clinical Trials near Sacramento, CA

Clinical Trials near La Jolla, CA

Clinical Trials near Orange, CA

Clinical Trials near Stanford, CA

Clinical Trials near Palo Alto, CA

Clinical Trials near Long Beach, CA

Clinical Trials near Duarte, CA

Clinical Trials near Oakland, CA

Clinical Trials near Torrance, CA

Other People Viewed

By Subject

Top Fallopian Tube Cancer Clinical Trials

Top Clinical Trials near Jacksonville, FL

Top Eczema Clinical Trials near Austin, TX

Top Clinical Trials near Montana

Top Clinical Trials near Foxboro, MA

145 Prostate Cancer Trials near Ventura, CA

Top Orthostatic Hypotension Clinical Trials

181 Clinical Trials near Ithaca, NY

Top Clinical Trials near Avondale, AZ

143 Diabetes Trials near Honolulu, HI

Top Clinical Trials near California

Top Spinal Cord Clinical Trials

By Trial

Semaglutide for Polycystic Ovary Syndrome

Injectable Cabotegravir + Rilpivirine for HIV

Avapritinib for Systemic Mastocytosis

Secukinumab for Polymyalgia Rheumatica

AMG 732 for Thyroid Eye Disease

Carvedilol for Early Parkinson's Disease

Buparlisib + Chemotherapy for Head and Neck Cancer

Immunotherapy + Chemotherapy for Sarcoma

Vorinostat for Uveal Melanoma

Stem Cell Transplant for Sickle Cell Disease

Acalabrutinib for Mantle Cell Lymphoma

Multidisciplinary Care Planning for Surgery in Veterans with Frailty

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial